Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Noa Ben-Baruch, Mariana Steiner et al.|npj Breast Cancer|2017Cited by 87
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Nicky Liebermann, Noa Ben-Baruch et al.|npj Breast Cancer|2017Cited by 70
The Tyr978X <i>BRCA1</i> Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer PatientsRonit Shiri‐Sverdlov, Eitan Friedman, Ruth Gershoni‐Baruch et al.|Public Health Genomics|2001Cited by 32
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapySalomon M. Stemmer, David Geffen, Mariana Steiner et al.|npj Breast Cancer|2019Cited by 30
Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is &gt;98%Salomon M. Stemmer, Nicky Liebermann, M. Steiner et al.|Cancer Research|2016Cited by 23